FDA approves pirtobrutinib for untreated CLL/SLL without 17p deletion based on BRUIN CLL-313 data. Read key nursing safety takeaways.
News|Articles|September 3, 2026
FDA Approves Zanidatamab-hrii in GEA: Key Takeaways for Oncology Nurses
Author(s)Alex Biese
Fact checked by: By ONN Staff
Oncology nursing guide to the FDA approval of zanidatamab-hrii for HER2+ gastroesophageal cancers, featuring insights from Joe Chichioco, RN, MPH.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) has approved the HER2-directed bispecific antibody zanidatamab-hrii (Ziihera) as a first-line therapy for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.
Related to this article
An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology nursing takeaways.
FDA approves belzutifan with lenvatinib for advanced clear cell RCC after PD-1/PD-L1 inhibitor failure. Review LITESPARK-011 data and nursing takeaways.
FDA approves lirafugratinib (Lyrfigtu) for FGFR2+ cholangiocarcinoma. Review REFOCUS trial data, 70 mg daily dosing, and nursing safety guidelines.
FDA approves lutetium lu 177 dotatate (Bravnetsa) as bioequivalent to Lutathera for GEP-NETs. Review key nursing takeaways and safety guidelines.
FDA approves imlunestrant plus abemaciclib for ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy.
FDA approves sNDA for taletrectinib (Ibtrozi) in ROS1+ NSCLC with updated DOR of nearly 50 months.
Dr. Wendy Harpham reflects on her journey as a physician and patient, emphasizing precise clinical communication in oncology care.
Advertisement
Advertisement